Video
Dr. Garmezy on the evolving treatment paradigm for progressive urothelial malignancies
Author(s):
“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.
Video Player is loading.
In this video, Benjamin Garmezy, MD, discusses the expanding armamentarium for the treatment of patients with progressive urothelial malignancies. Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.
Related Videos
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Study data point to gender disparities in oncology research citations
Related Content
